KBC Group NV Cuts Stock Position in Humana Inc. (NYSE:HUM)

KBC Group NV reduced its holdings in Humana Inc. (NYSE:HUM - Free Report) by 21.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,646 shares of the insurance provider's stock after selling 10,347 shares during the quarter. KBC Group NV's holdings in Humana were worth $12,241,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HUM. Pzena Investment Management LLC increased its position in shares of Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider's stock valued at $866,250,000 after buying an additional 1,955,375 shares during the period. Marshall Wace LLP increased its stake in shares of Humana by 118.9% in the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider's stock worth $532,564,000 after acquiring an additional 774,085 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Humana by 261,025.1% in the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider's stock worth $2,340,660,000 after acquiring an additional 738,701 shares during the last quarter. Steadfast Capital Management LP bought a new position in shares of Humana during the first quarter valued at $158,813,000. Finally, Baupost Group LLC MA bought a new position in Humana in the second quarter worth approximately $156,933,000. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Shares of HUM stock traded down $7.47 during mid-day trading on Friday, reaching $275.67. The company's stock had a trading volume of 1,842,901 shares, compared to its average volume of 2,301,719. The firm's 50-day moving average is $281.36 and its two-hundred day moving average is $331.81. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $527.18. The company has a market cap of $33.19 billion, a P/E ratio of 24.42, a PEG ratio of 2.17 and a beta of 0.52.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. On average, research analysts predict that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.28%. Humana's dividend payout ratio is currently 31.36%.

Analyst Ratings Changes

A number of brokerages have recently commented on HUM. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Piper Sandler downgraded Humana from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. KeyCorp began coverage on shares of Humana in a research report on Friday, October 11th. They set a "sector weight" rating for the company. Jefferies Financial Group lowered Humana from a "buy" rating to a "hold" rating and reduced their price target for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.